GlaxoSmithKline reports positive results from Phase III trial of shingles candidate vaccine
The trial met its primary endpoint showing that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo. HZ/su is
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
The company uses its Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body’s
The study, which recreated five earlier drug cardiac safety studies, utilized the proprietary Early Precision QT methodology developed by iCardiac Technologies. The results show highly significant improvement in
"This patent covers the significant innovations we have made in the delivery of therapeutic proteins into mitochondria," said Dalia Megiddo, MD, Chief Executive Officer of BioBlast. "We are